Clinical Trials of Primary and Secondary Prevention of Thrombosis and Restenosis

• References

• 1 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-1389
• 2 MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994 344. 633-638
• 3 Holvoet P, Collen D. Oxidized lipoproteins in atherosclerosis andthrombosis. FASEB J 1994; 8: 1279-1284
• 4 Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC, Vitamin E. consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328: 1450-1456
• 5 Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC, Vitamin E. consumption and the risk of coronary heart disease in women. N Engl J Med 1993; 328: 1444-1449
• 6 Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Emster VL. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037
• 7 Sullivan JM, Vander Zwaag R, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women Arch Intern Med 1990; 150: 2557-2562
• 8 Keaney Jr JF, Shwaery GT, Xu A, Nicolosi RJ, Loscalzo J, Foxall TL, Vita JA. 17 b-estrodiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation 1994; 89: 2251-2259
• 9 Heras M, Chesebro JH, Webster MW, Mruk JJ, Grill DE, Penny WJ, Bowie EJ, Badimon L, Fuster V. Hirudin, heparin and placebo during deep arterial injury inthe pig. The in vivo role of thrombin inplatelet-mediated thrombosis Circulation 1990; 82: 1476-1484
• 10 Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991; 84: 232-243
• 11 Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. 2d. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-7101
• 12 Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90: 1522-1536
• 13 Antman EM. for the TIMI-9A Investigators. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-1630
• 14 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Ila Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes.. Circulation. 1994; 90: 1631-1637
• 15 Dunwiddie C, Thom berry NA, Bull HG, Sardana M, Friedman PA, Jacobs JW, Simpson E, Antistasi n. a leech-derived inhibitor of factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site J Biol Chem 1989; 264: 16694-16699
• 16 Vlasuk CP. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemostas 1993; 70: 212-216
• 17 Coughlin SR, Vu TK, Hung DT, Wheaton TI. Characterization of a functional thrombin receptor. Issues and opportunities. J Clin Invest 1992; 89: 351-355
• 18 Zucker MB, Peterson J. Inhibition of adenosine diphosphate-induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion. Proc Soc Exp Biol Med 1968; 127: 547-551
• 19 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-2998
• 20 Verstraete M, Vermylen J, Roberts HR. (eds). The challenge of clinical trials in thrombosis. K Schattauer Verlag; Stuttgart: 1979
• 21 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS- 2. Lancet. 1988; 2: 349-360
• 22 Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Bri Med J Clin Res 1988; 296: 320-331
• 23 Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.. BMJ 1994; 308: 81-106
• 24 Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. II: Maintenance of vascular graft or arterial patency by antiplatelet therapy.. BMJ 1994; 308: 159-68
• 25 Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. Ill: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients.. BMJ 1994; 308: 235-46
• 26 Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S. et al. Randomized trial of prophylactic daily aspirin in British male doctors. BrMed J Clin Res Ed 1988; 296: 3136
• 27 Steering Committee of the Physicians ’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989; 321: 129-135
• 28 Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D, Elliot G, Panju A, Brant R. A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370-1376
• 29 Turpie AG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basil F, Klimek J, Hirsh J. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329: 524-529
• 30 Goodman SG, Langer A, Durica SS, Raskob GE, Comp PC, Gray RJ, Hall JH, Kelley RP, Hua TA, Lee RJ, Fuster V. Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group Am J Cardiol 1994; 74: 657-661
• 31 Meade TW. Low-intensity oral anticoagulation. In: Thrombosis and its management. Poller L, Thomson JM. eds. Churchill Livingstone; Edinburgh: 1993: 84-97
• 32 Meade TW, Roderick PJ, Brennan PJ, Wilkes HC, Kelleher CC. Extracranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemostas 1992; 68: 1-6
• 33 Clagett GP, Graor RA, Salzman EW. Antithrombotic therapy in peripheral arterial occlusive disease. Chest 1992; 102 Suppl (Suppl. 04) 516S-528S
• 34 Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molonu BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group N Engl J Med 1989; 321: 501-507
• 35 Herbert JM, Frehel D, Bemat A, Badorc A, Savi P, Delebassee D, et al. Gopidogre l. a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11: 180-198
• 36 Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975; 78: 3073-3076
• 37 Vermylen J, Deckmyn H. Thromboxane synthase inhibitors and receptor antagonists. Cardiovasc Dmgs Ther 1992; 6: 29-33
• 38 De Clerck F, Beetens J, de Chaffoy de Courcelles D, Freyne E, Janssen PA. R68070thromboxane A2 synthetase inhibition and thromboxane A2/ prostaglandin endoperoxide receptor blockade combined in one molecule. I: biochemical profile in vitro Thromb Haemostas 1989; 61: 35-12
• 39 Hoet B, Amout J, Van Geet C, Deckmyn H, Verhaeghe R, Vermylen J, Ridogre l. A combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma b-thromboglobulin levels in patients with documented peripheral arterial disease. Thromb Haemostas 1990; 64: 8790
• 40 The RAPT Investigators. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane Aj/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel versus Aspirin Patency Trial (RAPT).. Circulation. 1994; 89: 588-595
• 41 Plow EF, Ginsberg MH. Cellular adhesion: GPIIb/IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 1988; 9: 117-156
• 42 Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein Ilb-IIIa (integrin allbb3) mediated by fibrinogen and glycoprotein lb - von Willebrand factor J Biol Chem 1992; 267: 11300-11306
• 43 Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Deckmyn H, Vermylen J, Amout J. MK-383 (L700,462), a selective nonpeptide platelet glycoprotein Ilb/IIIa antagonist, is active in man. Circulation 1993; 88: 1512-1517
• 44 Collen D, Lu HR, Stassen JM, Yreys I, Yasuda T, Bunting S, Gold HK. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemostas 1994; 71: 95-102
• 45 Kereiakes D, Kleiman N, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton J, Weaver WD, McKee D, Sax FL. A dosing study in high-risk PTCA of MK-383, a platelet Ilb-IIIa antagonist. Circulation 1994; 90: 1-21 (Abstract)
• 46 Theroux P, White H, David D, Van de Werf F, Nienaber CA, Charbonnier B, Erhardt L, Gill J, Hillis WS, Jennings G, Tan LB, Deschenes N, Fitzpatrick V, Sax FL. A heparin-controlled study of MK-383 in unstable angina. Circulation 1994; 90: 1-231 (Abstract)
• 47 Theroux P, Kouz S, Knudtson ML, Kells C, Nasmith J, Roy L, Ave SD, Steiner B, Xiao Z, Rapold HJ. A randomized double-bind controlled trial with the non-peptide platelet GPIIb/IIIa antagonist RO 44-9883in unstable angina. Circulation 1994; 90: 1-232 (Abstract)
• 48 Harrington RA, Schulman SP, Kleiman NS, Lincoff AM, Goldschmidt-Clermont PJ, Joseph D, Sigmon KN, Parker J, Marchant K, Kitt MM. Profound,sustained and reversible platelet inhibition following administration of a glycoprotein Ilb/IIIa inhibitor with and without heparin in patients with unstable angina. Circulation 1994; 90: 1-232 (Abstract)
• 49 Ohman EM, Kleiman NS, Talley JD, Gacioch G, Navetta FI, Carney RJ, Worley S, Anderson HV, Cohen M, Kereiakes D, Joseph D, Sigmon KN, Topol EJ. for the IMPACT-AMI study Group. Simultaneous platelet glycoprotein Ilb/IIIa integrin blockade with accelerated tissue plasminogen activator in acute myocardial infarction. Circulation 1994; 90: 1-564 (Abstract)
• 50 Faulds D, Sorkin EM. Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease Drugs 1994; 48: 58398
• 51 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty.. N Engl J Med 1994; 330: 956-961
• 52 Topol EJ, Califf RM, Weisman HF, Eliss SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Wester M, Sigmon K, Anderson KM, Lee KL, Willerson JT. on behalf of The EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet Ilb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-886
• 53 Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994; 90: 2203-2206
• 54 Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US. Inhibition of neointimal hyperplasia by blocking avb3 integrin with a small peptide antagonist G-pen GRGDSPCA. J Vase Surg 1994; 19: 125-134